What is Lifesci Capital's Forecast for TCRX FY2025 Earnings?

Key Points

• Lifesci Capital has revised its FY2025 earnings estimate for TScan Therapeutics, now predicting a loss of $1.16 per share, down from $1.10.
• The consensus estimate for TScan's full-year earnings stands at ($1.12) per share, with current stock ratings showing a "Moderate Buy" sentiment.
• TScan Therapeutics reported a revenue of $3.08 million for the last quarter, significantly exceeding analysts' expectations of $1.31 million.

TScan Therapeutics, Inc. (NASDAQ:TCRX - Free Report) - Investment analysts at Lifesci Capital lowered their FY2025 earnings per share estimates for shares of TScan Therapeutics in a research report issued on Thursday, August 14th. Lifesci Capital analyst S. Slutsky now expects that the company will earn ($1.16) per share for the year, down from their previous estimate of ($1.10). The consensus estimate for TScan Therapeutics' current full-year earnings is ($1.12) per share.

TCRX has been the topic of a number of other research reports. Wall Street Zen raised TScan Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, July 12th. HC Wainwright cut their target price on shares of TScan Therapeutics from $15.00 to $10.00 and set a "buy" rating on the stock in a report on Wednesday, May 7th. Finally, Wedbush reaffirmed an "outperform" rating and set a $7.00 price target on shares of TScan Therapeutics in a report on Tuesday, August 12th. Five investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and an average price target of $7.80.

TScan Therapeutics Stock Performance

TCRX stock traded up $0.1050 during trading on Monday, hitting $1.8050. The company had a trading volume of 171,871 shares, compared to its average volume of 463,396. The firm has a market cap of $102.14 million, a PE ratio of -1.66 and a beta of 0.99. TScan Therapeutics has a 1-year low of $1.02 and a 1-year high of $6.2250. The firm has a 50-day moving average price of $1.68 and a 200-day moving average price of $1.65. The company has a quick ratio of 7.06, a current ratio of 7.06 and a debt-to-equity ratio of 0.18.

TScan Therapeutics (NASDAQ:TCRX - Get Free Report) last issued its quarterly earnings data on Tuesday, August 12th. The company reported ($0.28) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.28). The company had revenue of $3.08 million for the quarter, compared to analyst estimates of $1.31 million. TScan Therapeutics had a negative return on equity of 63.33% and a negative net margin of 1,964.88%.

Hedge Funds Weigh In On TScan Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the stock. BVF Inc. IL raised its position in shares of TScan Therapeutics by 63.6% during the first quarter. BVF Inc. IL now owns 4,889,474 shares of the company's stock valued at $6,747,000 after buying an additional 1,900,000 shares during the last quarter. Checkpoint Capital L.P. grew its stake in TScan Therapeutics by 14.9% during the first quarter. Checkpoint Capital L.P. now owns 2,017,650 shares of the company's stock worth $2,784,000 after buying an additional 261,663 shares during the last quarter. Jane Street Group LLC bought a new stake in TScan Therapeutics during the second quarter worth about $309,000. Dimensional Fund Advisors LP grew its stake in TScan Therapeutics by 108.5% during the fourth quarter. Dimensional Fund Advisors LP now owns 280,028 shares of the company's stock worth $851,000 after buying an additional 145,731 shares during the last quarter. Finally, Lynx1 Capital Management LP grew its stake in TScan Therapeutics by 2.5% during the fourth quarter. Lynx1 Capital Management LP now owns 5,357,347 shares of the company's stock worth $16,286,000 after buying an additional 132,747 shares during the last quarter. 82.83% of the stock is currently owned by hedge funds and other institutional investors.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.